JNJ 10181457 dihydrochloride

Discontinued Product

JNJ 10181457 dihydrochloride (Cat. No. 4019) has been withdrawn from sale for commercial reasons.
Cat.No. 4019 - JNJ 10181457 dihydrochloride | C20H28N2O.2HCl | CAS No. 544707-20-2
Description: H3 antagonist
Chemical Name: 4-[3-[4-[Piperidinyl]but-1-ynyl]benzyl]morpholine dihydrochloride
Purity: ≥98% (HPLC)
Citations (1)
Literature (4)

Biological Activity

Histamine H3 receptor antagonist (pKi values are 8.15 and 8.93 for rat and human H3 receptors respectively). Increases extracellular norepinephrine and acetylcholine levels in rat frontal cortex but does not stimulate dopamine release. Brain penetrant.

Licensing Information

Sold with the permission of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Technical Data

M. Wt 385.37
Formula C20H28N2O.2HCl
Storage Desiccate at RT
Purity ≥98% (HPLC)
CAS Number 544707-20-2
PubChem ID 10237424

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.


References are publications that support the biological activity of the product.

Bonaventure et al (2007) Histamine H3 receptor antagonists: from target identification to drug leads. Biochem.Pharmacol. 73 1084 PMID: 17129577

Esbenshade et al (2008) The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Br.J.Pharmacol. 154 1166 PMID: 18469850

Boggs et al (2009) JNJ-10181457, a selective non-imidazole histamine H3 receptor antagonist, normalizes acetylcholine neurotransmission and has efficacy in translational rat models of cognition. Neuropharmacology 56 1131 PMID: 19345233

View Related Products by Target

View Related Products by Product Action

View all Histamine H3 Receptor Antagonists

Keywords: JNJ 10181457 dihydrochloride, JNJ 10181457 dihydrochloride supplier, JNJ10181457, dihydrochloride, histamine, h3, receptors, antagonists, brain, penetrant, Histamine, H3, Receptors, 4019, Tocris Bioscience

1 Citation for JNJ 10181457 dihydrochloride

Citations are publications that use Tocris products. Selected citations for JNJ 10181457 dihydrochloride include:

Iida (2017) JNJ10181457, a histamine H3 receptor inverse agonist, regulates in vivo microglial functions and improves depression-like behaviours in mice. Biochem Biophys Res Commun 488 534 PMID: 28526411

Reviews for JNJ 10181457 dihydrochloride

There are currently no reviews for this product. Be the first to review JNJ 10181457 dihydrochloride and earn rewards!

Have you used JNJ 10181457 dihydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Histamine Receptors

Histamine Receptors Scientific Review

Written by Iwan de Esch and Rob Leurs, this review provides a synopsis of the different histamine receptor subtypes and the ligands that act upon them; compounds available from Tocris are listed.


Alzheimer's Poster

Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.


Asthma Poster

Asthma is one of the most common chronic diseases in the world, affecting over 300 million people. This poster highlights key pathways and new therapies used to treat the condition, including those currently in clinical development.